

Expert panel recommends Covaxin for ph 2/3 trials on 2-18 age group

New Delhi:

Bharat Biotech's Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between 2 and 18 years, official sources said. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.

The Subject Expert Committee on Covid-19 of the Central Drugs Standard Control Organisation on Tuesday deliberated upon Bharat Biotech's application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in those aged 2-18 years. The proposal was deliberated at the SEC meet on February 24 and the firm asked to submit a revised clinical trial protocol. PTI